Holoprosencephaly
Saturday, March 5, 2011
Low-risk of NSF with Dotarem (Gd-DOTA).
In a study presented in ECR 2011 independent prospective study supported by agencies in France have validated the low-risk status of the contrast agent Dotarem (Gd-DOTA). Detailed report on
Diagnostic Imaging
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment